



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

- sterile or nonsterile clinical samples by a new molecular assay. *J Clin Microbiol* 2003; **41**: 254–260.
7. Huletsky A, Giroux R, Rossbach V *et al.* New real-time PCR assay for rapid detection of methicillin-resistant *Staphylococcus aureus* directly from specimens containing a mixture of staphylococci. *J Clin Microbiol* 2004; **42**: 1875–1884.
 8. Witte W, Bräulke C, Cuny C *et al.* Emergence of methicillin-resistant *Staphylococcus aureus* with Panton–Valentine leukocidin genes in Central Europe. *Eur J Microbiol Infect Dis* 2005; **24**: 1–5.
 9. Enright M, Robinson D, Randle G, Feil E, Grundmann H, Spratt B. The evolutionary history of methicillin resistant *Staphylococcus aureus* (MRSA). *Proc Natl Acad Sci USA* 2002; **99**: 7687–7692.
 10. Okuma K, Iwakawa K, Turnridge JD *et al.* Dissemination of new methicillin-resistant *Staphylococcus aureus* clones in the community. *J Clin Microbiol* 2002; **40**: 4289–4294.
 11. Luong T, Ouyang S, Bush K, Lee CH. Type I capsule genes of *Staphylococcus aureus* carried in a staphylococcal cassette chromosome genetic element. *J Bacteriol* 2002; **184**: 3623–3629.
 12. Arbeit RD, Karakawa WW, Vann WF, Robbins JB. Prevalence of two newly described capsular polysaccharide types among clinical isolates of *Staphylococcus aureus*. *Diagn Microbiol Infect Dis* 1984; **2**: 85–91.
 13. Katayama T, Takeuchi F, Ito T, Ma X, Lei-Mizutani Kobayashi I, Hiramatsu K. Identification in methicillin-susceptible *Staphylococcus hominis* of an active primordial genetic element for the staphylococcal cassette chromosome *mec* of methicillin-resistant *Staphylococcus aureus*. *J Bacteriol* 2003; **185**: 2711–2722.
 14. Eveillard M, Lancian E, Barnaud G *et al.* Impact of screening for MRSA carriers at hospital admission on risk-adjusted indicators according to the imported MRSA colonization pressure. *J Hosp Infect* 2005; **59**: 254–258.

RESEARCH NOTE

Change in bacterial aetiology of peritoneal dialysis-related peritonitis over 10 years: experience from a centre in south-east Asia

C.-C. Szeto, C.-B. Leung, K.-M. Chow,
B. C.-H. Kwan, M.-C. Law, A. Y.-M. Wang,
S.-F. Lui and P. K.-T. Li

Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China

Corresponding author and reprint requests: C. C. Szeto, Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China
E-mail: ccszeto@cuhk.edu.hk

ABSTRACT

This study reviewed 1787 episodes of peritoneal dialysis (PD)-related peritonitis in 544 patients between 1994 and 2003. The overall rate of peritonitis was 0.68 episodes/year of PD, but decreased from 1.10 to 0.46 episodes/year between 1994 and 2003. The incidence of peritonitis caused by coagulase-negative staphylococci declined between 1994 and 1998 from 0.21 to 0.06 episodes/year of PD, coinciding with a reduction in the use of spike PD sets. There was a 60.1% response rate to antibiotics throughout the period, but the percentage of cases that required modification of the initial empirical antibiotic regimen rose from 13.6% to 58.7%, indicating that treatment should be individualised.

Keywords Coagulase-negative staphylococci, dialysis, infection, peritoneal dialysis, peritonitis, renal failure

Original Submission: 20 December 2004; **Revised Submission:** 10 March 2005; **Accepted:** 21 April 2005

Clin Microbiol Infect 2005; **11**: 837–839
10.1111/j.1469-0691.2005.01222.x

Peritonitis is the most important cause of treatment failure in peritoneal dialysis (PD) patients [1]. Peritonitis was common following the initial development of PD, but the incidence has decreased markedly during the past 15 years, probably as a result of improvements in connection technology [2,3]. Peritonitis rates nowadays are less than one episode/20 patient-months in most series [4,5]. The present study describes the change in distribution of causative organisms in PD-related peritonitis during a 10-year period in a single centre in Hong Kong.

All episodes of PD-related peritonitis between 1994 and 2003 in the renal unit of the Prince of Wales Hospital, Hong Kong, were reviewed. In total, 1787 episodes of peritonitis in 544 patients were identified. Data completeness was assured by the computerised Renal Registry. A diagnosis of peritonitis was based on at least two of the following criteria [6]: (1) abdominal pain or cloudy peritoneal dialysis effluent (PDE); (2) leukocytosis in PDE (white blood cells > 100/mL); and (3) positive Gram-stain or culture from PDE. Episodes with peritoneal eosinophilia but with a negative bacterial culture were excluded. Bacterial culture of PDE was performed

throughout the period in BacTAlert bottles (Organon Teknika, Durham, NC, USA), according to the recommendations of the International Society of Peritoneal Dialysis (ISPD) [7]. Isolation and identification of bacteria, as well as determination of antibiotic sensitivities, were performed according to the ISPD guidelines [7].

The overall clinical management of these patients has been described previously [8–12]. Empirical treatment of peritonitis, as summarised in Table 1, generally followed the ISPD guidelines, which were amended over time. Antibiotic regimens for individual patients were modified when culture results were available. Appropriate antibiotic therapy was continued for 14 days.

Table 1. Changes in the peritonitis management protocol in the renal unit during the 10-year period of the study

Period	Antibiotic regimen
January–December 1994 ^a	Imipenem–cilastatin ± vancomycin
January–December 1995	Ceftazidime + vancomycin
January–June 1996 ^a	Cefepime ± vancomycin
July 1996 to July 1998	Cefepime ± vancomycin; or ceftazidime + vancomycin
August 1998 to October 1998	Sulperazone
November 1998 to March 1999	Cefepime ± vancomycin
April 1999 to February 2001	Netilmicin + ceftazolin
March 2001 to February 2002 ^a	Ceftazidime + ceftazolin; or imipenem–cilastatin
March 2002 to date	Ceftazidime + ceftazolin

Dosages of all antibiotics generally followed those described by the International Society of Peritoneal Dialysis Ad Hoc Committee [7].

^aProspective studies underway [10–12].

Table 2. Microbiological causes of peritonitis episodes during a 10-year period

Organisms identified	No. of episodes (%)
Gram-positive organisms	722 (40.4)
<i>Staphylococcus aureus</i>	212 (11.9)
MSSA	174 (9.7)
MRSA	38 (2.1)
CNS	217 (12.1)
<i>Enterococcus</i> spp.	24 (1.3)
Other <i>Streptococcus</i> spp.	155 (8.7)
<i>Corynebacterium</i> spp.	20 (1.1)
Other diphtheroides	34 (1.9)
Others	60 (3.4)
Gram-negative organisms	520 (29.1)
<i>Pseudomonas</i> spp.	227 (12.7)
<i>Stenotrophomonas</i> spp.	13 (0.7)
<i>Escherichia coli</i>	109 (6.1)
<i>Klebsiella</i> spp.	47 (2.6)
<i>Acinetobacter</i> spp.	45 (2.5)
Others	79 (4.4)
Fungi	45 (2.5)
<i>Candida</i> spp.	41 (2.3)
Filamentous fungi	4 (0.2)
Mycobacteria	17 (1.0)
<i>Mycobacterium tuberculosis</i>	11 (0.6)
Atypical mycobacteria	6 (0.3)
Polymicrobial growth	192 (10.7)
Culture-negative	291 (16.3)
Total	1787

MSSA, methicillin-sensitive *S. aureus*; MRSA, methicillin-resistant *S. aureus*; CNS, coagulase-negative staphylococci.

Treatment response was defined as complete resolution of peritonitis with antibiotics alone (without relapse or catheter removal). Relapse was defined as recurrence of peritonitis caused by the same organism within 30 days of completion of antibiotic therapy [13]. All patients were followed for at least 3 months following the completion of treatment. Follow-up data were assured by the Computer Management System of the Hong Kong Hospital Authority.

The baseline demographic data of the 544 patients were similar to those of the overall PD population reported previously [14]. The overall rate of peritonitis was 0.68 episodes/year of PD. The microbiological causes are summarised in Table 2. A gradual reduction in the rate of peritonitis was observed during the 10-year period, from 1.10 episodes/year of PD in 1994 to 0.46 episodes/year of PD in 2003. The incidence of both Gram-positive and culture-negative peritonitis fell between 1994 and 1997, and then remained low. There was also a gradual decline in the incidence of Gram-negative peritonitis between 1994 and 2003. When individual bacterial species were considered, there was a substantial decline in the incidence of peritonitis caused by coagulase-negative staphylococci (CNS), and a less marked decline in *Staphylococcus aureus* peritonitis, while the incidence of peritonitis caused by *Streptococcus* spp. remained static. The incidence of peritonitis caused by CNS declined from 0.21 to 0.06 episodes/year of PD between 1994 and 1998, and then remained static. The incidence of peritonitis caused by *Pseudomonas* spp. also declined, from 0.11 to 0.04 episodes/year of PD between 2000 and 2003. In contrast, the incidence of peritonitis caused by *Escherichia coli* and *Klebsiella* spp. remained static.

There was a progressive reduction in the use of spike sets for PD between 1994 and 1998, which paralleled the decline in Gram-positive peritonitis. The average rate of response to antibiotic therapy was 60.1%, while 199 episodes (11.1%) required catheter removal. A combination of ceftazolin and ceftazidime, the regimen recommended by the current guidelines of the ISPD [7], yielded a response rate of 66.9%. The rate of response to antibiotic therapy remained static during the 10-year period (details not shown); however, the percentage of cases that required an alteration in the antibiotic regimen rose from 13.6% in 1994 to 58.7% in 2003.

The present study found that the overall incidence of PD-related peritonitis decreased by more than half during the 10-year study period. When specific organisms were examined, the incidence of peritonitis caused by CNS decreased by about 75%, while the incidence of that caused by *S. aureus* was halved. This declining incidence of Gram-positive peritonitis was not an unexpected finding. It is agreed generally that the incidence of peritonitis decreased markedly as a result of improvements in connection technology [2,3]. Almost all patients in the present series have used a disconnect system since 1998, and the incidence of Gram-positive peritonitis remained at a low but static level between 1998 and 2002, further supporting the role of the disconnect system. Interestingly, the incidence of Gram-positive peritonitis showed a further significant decrease in 2003. The precise reason for this further decrease remains unknown, but it may have resulted from the outbreak of severe acute respiratory syndrome (SARS) in Hong Kong, which reinforced the personal hygiene and aseptic precautions taken with these patients. Attention to such precautions has been proved to reduce the rate of infection in PD patients [15].

The increasing percentage of cases which required an alteration in the antibiotic regimen suggested that antibiotic resistance is becoming increasingly common. An increasing prevalence of infections in PD patients caused by methicillin-resistant CNS was noted by Holley *et al.* [16] in the 1980s, and, more recently, by Kim *et al.* [17]. Unfortunately, no data regarding the patterns of antibiotic resistance were available in the current retrospective analysis.

In summary, a gradual decline was observed in the incidence of PD-related peritonitis during the past 10 years, and appeared to be related partly to an increase in the utilisation of disconnect PD systems. There was, however, an increased need to modify the initial empirical antibiotic regimen during this period, indicating that treatment should be tailored individually.

ACKNOWLEDGEMENTS

This study was supported by the Chinese University of Hong Kong Research Account Number 6900570. We thank all the medical and nursing staff from the Renal Unit, Prince of Wales Hospital, Shatin, Hong Kong for their meticulous maintenance of the Renal Registry database.

REFERENCES

- Oreopoulos DG, Tzamaloukas AH. Peritoneal dialysis in the next millennium. *Adv Ren Replace Ther* 2000; **7**: 338–346.
- Levey AS, Harrington JT. Continuous peritoneal dialysis for chronic renal failure. *Medicine (Baltimore)* 1982; **61**: 330–339.
- Rotellar C, Black J, Winchester JF *et al.* Ten years' experience with continuous ambulatory peritoneal dialysis. *Am J Kidney Dis* 1991; **17**: 158–164.
- Li PK, Chan TH, So WY, Wang AY, Leung CB, Lai KN. Comparisons of Y-set disconnect system (Ultraset) versus conventional spike system in uremic patients on continuous ambulatory peritoneal dialysis: outcome and cost analysis. *Perit Dial Int* 1996; **16**(suppl 1): S368–S370.
- Li PK, Szeto CC, Law MC *et al.* Comparison of double-bag and Y-set disconnect systems in continuous ambulatory peritoneal dialysis—a randomised prospective multi-center study. *Am J Kidney Dis* 1999; **33**: 535–540.
- Vas SI. Peritonitis during CAPD. A mixed bag. *Perit Dial Bull* 1981; **1**: 47–49.
- Keane WF, Bailie GR, Boeschoten E *et al.* Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. *Perit Dial Int* 2000; **20**: 396–411.
- Szeto CC, Chow KM, Leung CB *et al.* Clinical course of peritonitis due to *Pseudomonas* species complicating peritoneal dialysis: a review of 104 cases. *Kidney Int* 2001; **59**: 2309–2315.
- Szeto CC, Chow KM, Wong TY, Leung CB, Li PK. Conservative management of polymicrobial peritonitis complicating peritoneal dialysis—a series of 140 consecutive cases. *Am J Med* 2002; **113**: 728–733.
- Lui SF, Cheng AB, Leung CB, Wong KC, Li PK, Lai KN. Imipenem/cilastatin sodium in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitis. *Am J Nephrol* 1994; **14**: 182–186.
- Li PK, Ip M, Law MC *et al.* Use of intra-peritoneal (IP) cefepime as monotherapy in the treatment of CAPD peritonitis. *Perit Dial Int* 2000; **20**: 232–234.
- Leung CB, Szeto CC, Chow KM *et al.* Cefazolin plus ceftazidime versus imipenem/cilastatin monotherapy for treatment of CAPD peritonitis—a randomized controlled trial. *Perit Dial Int* 2004; **24**: 440–446.
- British Society for Antimicrobial Chemotherapy. Diagnosis and management of peritonitis in continuous ambulatory peritoneal dialysis. *Lancet* 1987; **1**: 845–849.
- Szeto CC, Wong TY, Leung CB *et al.* Importance of dialysis adequacy in mortality and morbidity of Chinese CAPD patients. *Kidney Int* 2000; **58**: 400–407.
- Ludlam HA, Young AE, Berry AJ, Phillips I. The prevention of infection with *Staphylococcus aureus* in continuous ambulatory peritoneal dialysis. *J Hosp Infect* 1989; **14**: 293–301.
- Holley JL, Bernardini J, Johnston JR, Piraino B. Methicillin-resistant staphylococcal infections in an outpatient peritoneal dialysis program. *Am J Kidney Dis* 1990; **16**: 142–146.
- Kim DK, Yoo TH, Ryu DR *et al.* Change in causative organisms and their antimicrobial susceptibilities in CAPD peritonitis: a single center experience over one decade. *Perit Dial Int* 2004; **24**: 424–432.